Internalized Stigma in Pediatric Psoriasis: A Comparative Multicenter Study

Erkan Alpsoy, Mualla Polat, Ibrahim Halil Yavuz, Pelin Kartal, Didem Didar Balci, Ayse Serap Karadag, Asli Bilgic, Ercan Arca, Bilge Fettahlioglu Karaman, Selma Emre, Esra Adisen, Neslihan Sendur, Ozlem Bilgic, Ayca Cordan Yazici, Basak Yalcin, Rafet Koca, Kamer Gunduz, Murat Borlu, Tulin Ergun, Pinar Dursun, Serap Gunes Bilgili, Asli Surer Adanir, Ayla Gulekon, Gizem Yagcioglu, Ertan Yilmaz, Ufuk Kavuzlu, Yesim Senol, Ayse Serap Karadag, Asli Bilgic, Ercan Arca, Bilge Fettahlioglu Karaman, Selma Emre, Esra Adisen, Neslihan Sendur, Ozlem Bilgic, Ayca Cordan Yazici, Basak Yalcin, Rafet Koca, Kamer Gunduz, Murat Borlu, Tulin Ergun, Pinar Dursun, Serap Gunes Bilgili, Asli Surer Adanir, Ayla Gulekon, Gizem Yagcioglu, Ertan Yilmaz, Ufuk Kavuzlu, Yesim Senol

Department of Dermatology and Venereology, Akdeniz University School of Medicine, Antalya, Department of Dermatology and Venereology, Abant Izzet Baysal University School of Medicine, Bolu, Department of Dermatology and Venereology, Van Yuzuncu Yil University School of Medicine, Van, Department of Dermatology and Venereology, University of Health Sciences Ankara Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Department of Dermatology and Venereology, Izmir Tepecik Education and Research Hospital, Izmir, Department of Dermatology and Venereology, Istanbul Medeniyet University School of Medicine, Istanbul, Department of Dermatology and Venereology, Guven Hospital, Ankara, Department of Dermatology and Venereology, Cukurova University School of Medicine, Adana, Department of Dermatology and Venereology, Yildirim Beyazit University Ankara Ataturk Education and Research Hospital, Ankara, Department of Dermatology and Venereology, Gazi University Faculty of Medicine, Ankara, Department of Dermatology and Venereology, Adnan Menderes University School of Medicine, Aydin, Department of Dermatology and Venereology, Selcuk University School of Medicine, Konya, Department of Dermatology and Venereology, Mersin University School of Medicine, Mersin, Department of Dermatology and Venereology, Ankara Numune Training and Research Hospital, Ankara, Department of Dermatology and Venereology, Balent Ecevit University School of Medicine, Zonguldak, Department of Dermatology and Venereology, Celal Bayar University School of Medicine, Manisa, Department of Dermatology and Venereology, Erciyes University School of Medicine, Kayseri, Department of Dermatology and Venereology, Marmara University School of Medicine, Istanbul, Department of Dermatology and Venereology, Yildirim Beyazit University Ankara Ataturk Education and Research Hospital, Ankara, Department of Medical Education, Akdeniz University School of Medicine, Antalya, Turkey

Background: Internalized stigma, adoption of negative attitudes and stereotypes of the society regarding persons’ illness, has not been studied previously in pediatric psoriasis patients. Objective: We aimed to investigate the internalized stigma in pediatric psoriasis patients and to determine differences according to factors affecting internalized stigma compared to adult psoriasis patients. Methods: This multicenter, cross-sectional, comparative study included 125 pediatric (55 female, 70 male; mean age ± standard deviation [SD], 14.59 ± 2.87 years) and 1,235 adult psoriasis patients (577 female, 658 male; mean age ± SD, 43.3 ± 13.7 years). Psoriasis Internalized Stigma Scale (PISS), Dermatology Life Quality Index (DLQI), Perceived Health Status (PHS), and the General Health Questionnaire (GHQ)-12 were the scales used in the study. Results: The mean PISS was 58.48 ± 14.9 in pediatric group. When PISS subscales of groups were compared, the pediatric group had significantly higher stigma resistance (p = 0.01) whereas adult group had higher scores of alienation (p = 0.01) and stereotype endorsement (p = 0.04). There was a strong correlation between mean values of PISS and DLQI (r = 0.423, p = 0.001). High internalized stigma scores had no relation to either the severity or localization of disease in pediatric group. However, poor PHS (p = 0.007) and low-income levels (p = 0.03) in both groups, and body mass index (r = 0.181, p = 0.04) in the pediatric group were related to high PISS scores. Conclusion: Internalized stigma in pediatric patients is as high as adults and is related to poor

ORCID: https://orcid.org/0000-0001-7049-0170

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology
quality of life, general health, and psychological illnesses. Unlike adults, internalized stigma was mainly determined by psoriasis per se, rather than disease severity or involvement of visible body parts, genitalia or folds. (Ann Dermatol 32(3) 181~188, 2020)

Keywords: Child, Inflammation, Psoriasis, Quality of life, Stigmatization

INTRODUCTION

The skin and adnexa, as significant features of our external appearance, contribute to our social standing. Diseases localized to the visible or special body parts (e.g. genitalia) can lead to significant psychosocial problems, including stigmatization. Psoriasis, being the most common systemic inflammatory disease, causes psychosocial morbidity and cumulative disability over a patient’s lifetime. Psoriatic lesions often affect visible parts of the body that may discriminate the individual from others, in other words, stigmatize the patient. Internalized stigma, another dimension of the stigma, is the feeling of stigma experienced by the individual even though he or she is not stigmatized by the society. The individual accepts negative stereotypes about the illness created by society and withdraws himself/herself from society with emotions such as worthlessness and shame. The patient presumes that other people have a reaction towards his/her illness and eventually withdraws him/herself from the social life ending up with decreased self-esteem and life-satisfaction, increased depression and suicidality as well as difficulty in coping with the illness. The internalized stigma may affect the quality of life and treatment response negatively.

Current knowledge on internalized stigma in patients with psoriasis is extremely limited. Our recent study has shown that psoriasis patients experience high levels of internalized stigma, which is associated with disease severity, poorer quality of life, negative perceptions of general health and psychological illnesses. The internalized stigma was more pronounced in patients with involvement of visible body parts, genital organs, folds or joints. In line with our findings, a recent study by van Beugen et al. who investigated the predictor variables for perceived stigmatization using 6-item subscale of the Impact of Chronic Skin Disease on Daily Life Questionnaire revealed 73% of patients to experience some degree of stigmatization. The authors reported an association with a higher impact on daily life, lower education, higher disease visibility, severity, and duration, higher levels of social inhibition and having a Type D personality (personality composed of two traits: negative affect and social inhibition; experiencing negative emotions and abstain from sharing these emotions with others due to anxieties concerning their potential response and fears over how they will be perceived).

Since both studies focused on internalized stigma in adult psoriasis patients, data on internalized stigma in the pediatric group was lacking. Therefore, we aimed to investigate the internalized stigma state in pediatric psoriasis patients and to determine whether there are differences according to factors affecting internalized stigma compared to adult psoriasis patients.

MATERIALS AND METHODS

This multicenter, prospective cross-sectional, the comparative study included 125 pediatric (55 female, 70 male; mean age±standard deviation [SD], 14.59±2.87 years) and 1,235 adult psoriasis patients (577 female, 658 male; mean age±SD, 43.3±13.7 years) from 18 study centers from different geographic regions of Turkey between 2014 and 2016. In order to ensure homogeneous distribution of patients in the centers, the ratio of pediatric/adult patients taken from each center was planned to be 1/10. This study used some of the questionnaires to determine internalized stigmatization in psoriasis, and part of this data has been used in a previous article. The ages of pediatric psoriasis patients ranged from 10 to 18 years. Patients who did not have any previously diagnosed psychiatric disease and willing to participate in the study were included. Informed consent was obtained from all the patients or his/her guardians, and the study was conducted according to the Declaration of Helsinki Principles. The study was approved by the Ethics Committee of Akdeniz University School of Medicine (no. 70904504/215). The sociodemographic characteristics of the patients and other parameters, which may influence internalized stigma and quality of life (age, sex, duration of disease and age at onset, history of psoriasis in the family, comorbidity diseases, income level, education level, previous hospitalization for her/his illness, active treatment during the study) were recorded. The subtype of psoriasis has been defined and body mass index (BMI) was calculated. Active involvement of scalp, face, hands, genital area, folds (inverse psoriasis), fingernails, and/or joints were recorded. Nail Psoriasis Severity Index (NAPSI; in all fingernails) was calculated. Physician’s Global Assessment (PGA) has been used as an alternative severity scale when Psoriasis Area Severity Index (PASI) did not function well (palmoplantar plaque psoriasis [PP], inverse psoriasis [IP], palmoplantar pustular psoriasis [PPP]). PGA was used to assess the most severely
involved hand, foot or folded areas.

**Data collection scales**

1) **Internalized stigma scale**

Internalized stigma scale (ISS) was developed by Ritsher et al. for mental illnesses and has been adapted for many diseases other than psychological disorders. Likert scale is the most commonly used rating scale to measure respondents' agreement level. It is an ordinal scale used by respondents to express how much they agree or disagree with a particular statement. ISS is also a Likert-type scale composed of 29 items measuring the internalization of stigma experienced by the patients. It has five dimensions; alienation (6 items; measuring the subjective experience of being less than a full member of society), perceived discrimination (5 items; capturing their perception of the way that they currently tend to be treated by public), social withdrawal (6 items; capturing their degree of avoidance from personal interactions and public) and stigma resistance (5 items; trying to capture the experience of resisting or being unaffected by internalized stigma). ISS values range from 4 to 91. High ISS score points out more severe internalized stigma. In our country, the reliability and validity study of the ISS for mental illnesses has been carried out. ISS in dermatological diseases was first studied in psoriasis and has been shown to be a reliable and valid scale in identifying internalized stigma.

2) **Perceived Health Status**

Perceived Health Status (PHS) is a five-point Likert-type scale measuring general health with a single question. In the analysis, Likert scorings are classified as 1, 2, 3: “worse than good” and 4 and 5: “good”. PHS has been widely used in the evaluation of health problems, the burden of diseases and health needs at the population level since it is often difficult and expensive to determine objective measures of health status.

3) **General Health Questionnaire-12**

General Health Questionnaire (GHQ)-12 has been developed by David Goldberg in order to define mental status in public and in primary healthcare establishments. Being a quick, reliable and valid questionnaire, GHQ-12 is ideal for research studies. It has a high sensitivity and specificity. Although GHQ-12 has been developed to distinguish general mental disorders, it contains items questioning basic symptoms of depression including enjoyment, sense of calm, distractibility and sleeplessness. For this reason, it has been noted that GHQ-12 can also be used in screening of depression in centers where psychiatrists are not available. Validity and reliability of Turkish version has been shown. On the day of enrollment, PASI and Body Surface Area (BSA) were calculated by the physician. At the same time, all patients were asked to complete ISS adapted to psoriasis (PISS), Dermatology Life Quality Index (DLQI), PHS and GHQ-12 forms. This study enrolled only patients who admitted to specialized centers and used self-reported questionnaires. Thus, this could create a potential bias and limitation when generalizing the results of this study to the entire population.

**Statistics**

Descriptive statistics such as mean, standard deviation and percentage were used as statistical methods. In the analysis of the data, the significance test of the difference between the two means was used. Additionally, the correlation has been applied for correlation detecting statistics. The analyses were performed using IBM SPSS Statistics ver. 22.0 (IBM Corp., Armonk, NY, USA), and p-values of less than 0.05 was considered statistically significant.

**RESULTS**

The mean age of the pediatric patient group was 14.59 ± 2.87 years (10–18 years) and the mean age at onset of the disease was 9.68 ± 4.1 years (1–17 years). The mean age of the adult patient group was found to be 43.34 ± 13.7 years (19–85 years) and the onset age of the disease, 29.96 ± 14.67 years (1–84 years). Male patients were 56.0% of all pediatric patients, and 35.2% of them had a family history of psoriasis. Chronic plaque psoriasis (80.0%) was the most common psoriasis type. PHS score was defined as “bad” in 45.6% of all patients. Only 3.2% of the patients were receiving local and/or systemic psoriasis treatment during the study. The rest of the socio-demographic and clinical features of pediatric psoriasis patients are presented in Table 1. Male patients were 46.7% of adult patients, and 34.1% of them had a family history of psoriasis. Chronic plaque psoriasis (73.4%) was the most common psoriasis type. PHS score was defined as “bad” in 59.2% of all patients. During the course of the study, 85.7% of the patients were receiving local and/or systemic psoriasis treatment(s).

There was no significant difference in the mean values of PISS between pediatric and adult psoriasis patients (58.48 ± 14.9 vs. 60.6 ± 15.0, respectively; p = 0.13). The lowest value among the five subscales of PISS was the perceived discrimination whereas the highest value belonged to stigma.
Table 1. Sociodemographic and clinical characteristics of the pediatric psoriasis patients

| Variable          | Value  |
|-------------------|--------|
| **Sex**           |        |
| Male              | 70 (56.0) |
| Female            | 55 (44.0) |
| **Income level**  |        |
| Low (income is less than the expense) | 61 (48.8) |
| Moderate (income is equal to expense) | 22 (17.6) |
| High (income is over the expense)    | 42 (33.6) |
| **Education**     |        |
| Primary school graduate            | 27 (21.6) |
| Secondary school graduate          | 50 (40.0) |
| High school graduate              | 46 (36.8) |
| Postgraduate                    | 1 (0.8)  |
| Faculty                        | 1 (0.8)  |
| **Comorbidity**    |        |
| No                             | 121 (96.8) |
| Yes                            | 4 (3.2)   |
| **Perceived health status**      |        |
| Very good                     | 1 (0.8)   |
| Good                          | 11 (8.8)  |
| Moderate                     | 38 (30.4) |
| Bad                          | 57 (45.6) |
| Very bad                     | 18 (14.4) |
| **Face involvement**          |        |
| No                            | 102 (81.6) |
| Yes                          | 23 (18.4) |
| **Scalp involvement**         |        |
| No                            | 53 (42.4)  |
| Yes                          | 72 (57.6) |
| **Hand involvement**          |        |
| No                            | 101 (80.8) |
| Yes                          | 24 (19.2) |
| **Genital area involvement**  |        |
| No                            | 112 (89.6) |
| Yes                          | 13 (10.4) |
| **Inverse involvement**       |        |
| No                            | 115 (92.0) |
| Yes                          | 10 (8.0)  |
| **Nail involvement**          |        |
| No                            | 104 (83.2) |
| Yes                          | 21 (16.8) |
| **Articular involvement**     |        |
| No                            | 124 (99.2) |
| Yes                          | 1 (0.8)   |
| **Clinical**                 |        |
| Chronic plaque psoriasis      | 100 (80.0) |
| Guttate psoriasis             | 28 (22.4) |
| Palmoplantar psoriasis        | 1 (0.8)   |
| Pustular psoriasis            | 8 (6.4)   |
| **Family history**            |        |
| No                            | 81 (64.8)  |
| Yes                          | 44 (35.2)  |
| **Inpatient treatment**       |        |
| No                            | 106 (84.8) |
| Yes                          | 19 (15.2)  |

Values are presented as number (%) or number (mean±standard deviation). PASI: Psoriasis Area Severity Index, BSA: Body Surface Area. *More than one option has been marked. †Inpatient treatment’ describes patients with a history of treatment at an inpatient dermatology clinic during the whole period of their diseases. ‡Active treatment’ describes patients who were on therapy of any kind during the study period.

Table 1. Continued

| Variable          | Value  |
|-------------------|--------|
| Active Treatment† |        |
| No                | 121 (96.8) |
| Yes               | 4 (3.2)   |
| Disease severity  |        |
| PASI              | 125 (5.2±5.4) |
| BSA               | 125 (9.6±8.1) |

To evaluate the criterion validity of PISS, the relationships between PISS and DLQI, PASI, and BSA were examined. In the pediatric patient group, a statistically significant correlation was found between the mean values of PISS and DLQI (r=0.423, p=0.001). However, there was no statistically significant correlation between the PASI (5.2±5.4) and PISS values (r=0.122, p=0.192). There was a weak but statistically significant relationship between BSA (9.6±8.1) and PISS only on the alienation subscale (r=0.207, p=0.03). In the adult patient group, we also observed a significant positive correlation between PISS (13.3±17.1) and DLQI values (r=0.418, p=0.001). There was no significant difference between pediatric psoriasis and adult psoriasis patients in terms of DLQI (10.4±8.9 and 11.2±8.9, p=0.36, respectively). Unlike pediatric patients, significant differences were also found between mean total PISS values and PASI (r=0.214, p=0.001) and BSA (r=0.233, p<0.01) in adult patients (Table 3). A statistically significant correlation was found between GHQ-12 and mean total PISS values (r=0.342 p=0.01), BSA (r=0.100, p<0.001) and DLQI (r=0.306, p<0.001). There was no significant difference between pediatric resistance in pediatric patients. In the adult patients, the lowest value belonged to the perceived discrimination subscale, while the highest value belonged to the subscale of stereotype endorsement. Of the PISS subscales, stigma resistance in the pediatric patients (13.4±3.9, 11.9±3.2, p=0.01), and alienation (12.9±4.4, 11.7±3.9, p=0.01) and stereotype endorsement (13.4±3.9, 12.7±4.2, p=0.04) in adult psoriasis patients were significantly higher when compared with each other (Table 2). When we evaluated the relationship between mean PISS scores and sex, there was no significant difference in pediatric (female, 56.1±13.2; male, 60.3±16.1; p=0.121) and adult patients (female, 60.1±15.0; male, 61.1±15.0; p=0.296).
Table 2. PISS subscales in pediatric and adult psoriasis patients

| PISS and its subscales | Pediatric psoriasis (n=125) | Adult psoriasis (n=1,235) | p-value |
|------------------------|----------------------------|--------------------------|---------|
| PISS                   | 58.48±14.9 (32∼91)         | 60.6±15.0 (29∼91)        | 0.13    |
| Alienation             | 11.7±3.9 (6∼23)            | 12.9±4.4 (6∼24)          | 0.01    |
| Stereotype endorsement | 12.7±4.2 (7∼27)            | 13.4±3.9 (7∼28)          | 0.04    |
| Perceived discrimination | 9.5±3.0 (5∼20)        | 9.7±3.4 (5∼41)           | 0.27    |
| Social withdrawal      | 11.4±4.1 (6∼24)            | 12.5±4.6 (6∼24)          | 0.07    |
| Stigma resistance      | 13.4±3.9 (5∼23)            | 11.9±3.2 (5∼57)          | 0.01    |

Values are presented as mean±standard deviation (range). PISS: Psoriasis Internalized Stigma Scale.

Table 3. Correlation coefficient between PISS subscales and DLQI, PASI, BSA, and GHQ-12 in pediatric and adult psoriasis patients

| PISS and its subscales | Pediatric psoriasis (n=125) | Adult psoriasis (n=1,235) |
|------------------------|----------------------------|--------------------------|
|                        | DLQI | PASI | BSA | GHQ-12 | DLQI | PASI | BSA | GHQ-12 |
| Alienation             | 0.304 | 0.175 | 0.207 | 0.275 | 0.371 | 0.230 | 0.251 | 0.376 |
| p-value                | 0.01  | 0.175 | 0.103 | 0.05  | 0.000 | 0.001 | 0.001 | 0.001 |
| Stereotype endorsement | 0.405 | 0.073 | 0.073 | 0.352 | 0.397 | 0.166 | 0.170 | 0.339 |
| p-value                | <0.001 | 0.44 | 0.44 | 0.03  | 0.001 | 0.001 | 0.001 | 0.001 |
| Perceived discrimination | 0.387 | 0.144 | 0.159 | 0.358 | 0.363 | 0.204 | 0.233 | 0.303 |
| p-value                | <0.001 | 0.12 | 0.09 | 0.01  | 0.001 | 0.001 | 0.001 | 0.001 |
| Social withdrawal      | 0.304 | 0.144 | 0.128 | 0.254 | 0.359 | 0.211 | 0.216 | 0.337 |
| p-value                | 0.01  | 0.119 | 0.175 | 0.03  | 0.001 | 0.001 | 0.001 | 0.001 |
| Stigma resistance      | 0.228 | −0.015 | −0.26 | 0.039 | 0.040 | −0.023 | 0.014 | −0.050 |
| p-value                | 0.01  | 0.868 | 0.786 | 0.67  | 0.597 | 0.450 | 0.641 | 0.001 |

PISS: Psoriasis Internalized Stigma Scale, DLQI: Dermatology Life Quality Index, PASI: Psoriasis Area Severity Index, BSA: Body Surface Area, GHQ-12: General Health Questionnaire-12.

psoriasis and adult psoriasis patients in terms of GHQ-12 (2.7±2.3 and 2.6±2.5; p=0.79, respectively) (Table 3). When the PHS were assessed, the mean PISS scores of those patients with a PHS of “worse than good” were significantly higher than that of those with a PHS of “good” in both pediatric (62.4±13.7 vs. 55.5±15.1; p=0.007) and adult patients (64.3±15.0 vs. 55.2±13.4; p=0.001). Similarly, the mean DLQI score of those patients with a PHS of “worse than good” was found to be significantly higher than that of those with a PHS of “good” in both pediatric (13.4±8.0 vs. 8.5±7.0; p=0.003) and adult patients (12.9±8.5 vs. 8.7±9.1, p=0.001). There was no significant relationship in terms of scales used in the study when the pediatric patients were compared to each other according to the different age groups (10∼14 vs. 15∼18).

Significantly higher PISS scores were observed in the group of patients with low-income level (patients whose monthly income do not cover their expense) in both pediatric (63.4±14.1, 57.2±14.7, p=0.03) and adult patients (63.3±15.7, 58.7±14.3, p=0.01). There was no significant difference in both groups (p=0.82). No significant correlation was found between the mean disease duration (4.8±3.2 years) and mean PISS values in the pediatric patients (r=0.29, p=0.749). However, there was a weak but significant relationship between the mean duration of illness (13.3±11.1) and mean PISS values in adult patients (r=0.077, p=0.008). When the relationship between the history of psoriasis in the family and mean PISS values was evaluated, no significant difference was found in either group. A weak but statistically significant relationship was found between BMI and mean PISS values in the pediatric patient group (r=0.046, p=0.118). When we evaluated the relationship between psoriasis clinical subgroups and the mean total PISS score in pediatric patients, psoriasis vulgaris patients showed significantly higher PISS values than guttate psoriasis patients (58.9±15.0, 56.9±14.4, p=0.042, respectively). In adult patients, mean PISS values were significantly higher in erythrodermic psoriasis (75.1±11.8) and generalized pustular psoriasis (70.2±11.6) than guttate psoriasis (56.1±14.3) and palmoplantar psoriasis (56.4±15.2, p<0.05).

The mean PISS score in patients with nail involvement in pediatric patients was not statistically significantly different.
from those without nail involvement. Similarly, there was no statistically significant difference between patients with and without involvement in other visible areas of the body, such as the scalp, face, and hand. There was no significant difference between patients with IP and genital area involvement and those without. On the other hand, the mean PISS values of adult patients with the active scalp, face, hand, genital organs and fingernails and IP patients were significantly higher than those without (Table 4).

**DISCUSSION**

In this multicenter study, comparing 125 pediatric and 1,235 adult psoriasis patients, we found high levels of internalized stigma state in the pediatric group showing a parallel course with the poor quality of life, general health status, and psychological disorders. These findings are concordant with two previous studies which included only adult psoriasis patients. In addition to causing significant psychosocial impairment, internalized stigma has negative effects on the utilization of health care and treatment compliance, subsequently increased disease severity. Therefore, it can be proposed that internalized stigma may have an effect on disease severity in psoriasis patients. Moreover, in pediatric psoriasis patients, unlike adults, there was no relationship between high levels of internalized stigma and the severity of the disease. This finding may have a few explanations. Having a chronic disease which can be perceived by others may suffice a child to develop significant stigmatization independent from severity. The main cause of stigma could be due to multiple hospital admissions accompanied by parents.

Another interesting finding in our study was that besides extensiveness and/or severity of psoriasis, the involvement of visible body parts, genital area or folds were not found to be related with the high levels of internalized stigma in pediatric psoriasis patients. Regarding the mean age of our pediatric group, this finding may be explained by the lack of importance of genitalia involvement in sexually inactive young children. Also, pediatric cases may have better motivation for the use of medications because of relatively short disease duration compared to adults. In fact, adults may get tired of using medications on long-term basis.

We did not find a significant correlation between mean disease duration and PISS in the pediatric patients, while there was a significant relationship in the adult patients. As expected, the duration of the disease is longer in adult patients (13.3 ± 11.1 vs. 4.8 ± 3.2). This result is consistent with our previous study, and the internalized stigma increases as the disease duration increases.

We also observed some differences in the PISS subscales. Alienation and stereotype endorsement were significantly higher in adult patients. We can propose that, similar to the society, adult psoriasis patients also have some prejudice about the disease, leading to internalized negative stereotype judgments of the society for themselves. On the other hand, stigma resistance subscale was significantly higher in the pediatric group. In contrast to the other four subscales, the resistance to stigma subscale assesses the individual’s ability to cope with illness and resistance to stigmatization. These findings may implicate pediatric cases to be insufficient for developing coping strategies. As internalized stigma may cause a vicious cycle, reducing patients’ resistance to stigmatization, management of pediatric psoriasis patients may include educational approaches focusing enhancement of coping strategies and diminishing stigmatization.

Table 4. Relationship of mean Psoriasis Internalized Stigma Scale (PISS) with psoriasis localizing on the visible parts of body, nail, genital area or mucosa, inverse and articular psoriasis in pediatric and adult psoriasis patients

| Clinical features                   | Pediatric psoriasis (n=125) | Adult psoriasis (n=1,235) |
|------------------------------------|-----------------------------|---------------------------|
|                                   | Yes | No | p-value | Yes | No | p-value |
| Scalp involvement                  | 58.6±14.5 | 58.3±15.6 | 0.905 | 62.1±15.1 | 58.7±14.7 | <0.01 |
| Face involvement                   | 56.1±15.2 | 59.0±14.9 | 0.395 | 64.9±15.0 | 59.7±14.9 | <0.01 |
| Hand involvement                   | 59.0±14.3 | 58.3±15.2 | 0.841 | 62.4±15.3 | 59.4±14.7 | <0.01 |
| Nail involvement                   | 57.2±12.9 | 58.7±15.4 | 0.688 | 62.4±15.1 | 59.5±14.9 | <0.01 |
| Genital organ involvement          | 60.1±13.1 | 58.3±15.1 | 0.699 | 64.3±15.3 | 59.8±14.9 | <0.01 |
| Inverse psoriasis                  | 56.6±17.4 | 58.6±15.1 | 0.679 | 65.0±15.5 | 59.8±14.8 | <0.01 |

Values are presented as mean±standard deviation.
of PISS and DLQI. This may indicate internalized stigma to influence the quality of life significantly. Thus, in addition to disease control, coping with stigmatization may be required for improvements in quality of life.

The mean PISS scores of those patients with a PHS of “worse than good” were significantly higher than that of those with a PHS of “good” in both pediatric and adult psoriasis patients. Similarly, there was a statistically significant correlation between the mean values of GHQ-12 and the PISS. All these results indicate that internalized stigma, general health, and mental illnesses tend to be parallel to each other, and this is compatible with the results in mental illnesses17. Taken together, these findings suggest that strategies for correcting internalized stigma may be effective in improving the quality of life and negative health outcomes in psoriasis patients. Studies conducted in psychiatric disorders17 support that such initiatives can positively affect treatment outcomes and quality of life.

In both groups, PISS scores were significantly higher in those with lower income. This, in accordance with prior studies, indicates that patients with higher income levels can cope better with internalized stigma and, in general, with illnesses17.

Our study also had some limitations. Because of the cross-sectional study design, causality could not be established. Another general limitation of the study was the use of self-reported questionnaires. Also, we enrolled only patients who admitted to specialized centers. Therefore, this should be taken into account when generalizing the results of this study to the entire population. On the other hand, the major strengths of our study were to study a large nationwide sample of pediatric and adult psoriasis patients and to investigate internalized stigma with clinical and quality of life correlations.

In conclusion, our study shows that pediatric psoriasis patients internalize the negative stereotype judgments of the society for themselves which may be related with their quality of life, general health status, and psychological well-being. Therefore, it would be useful to develop strategies to ameliorate the internalized stigma and improve psychosocial health in psoriasis patients. The high levels of internalized stigma show a parallel course with the patient’s self-efficacy and self-esteem reduction, which affects the patient’s adherence to treatment negatively. The inclusion of educational approaches to the treatment plans as well as psychotherapy in selected patients that address the internalized stigma may be expected to increase treatment compliance. Educational studies conducted through written and visual media tools are of great importance in the fight against stigmatization in society.

**CONFLICTS OF INTEREST**

The authors have nothing to disclose.

**ORCID**

Erkan Alpsoy, https://orcid.org/0000-0001-7049-0170
Mualla Polat, https://orcid.org/0000-0001-9226-5134
Ibrahim Halil Yavuz, https://orcid.org/0000-0003-0819-2871
Pelin Kartal, https://orcid.org/0000-0001-7310-8635
Didem Didar Balci, https://orcid.org/0000-0002-5012-4824
Ayse Serap Karadag, https://orcid.org/0000-0003-4333-8274
Asli Bilgic, https://orcid.org/0000-0001-7910-7908
Ercan Arca, https://orcid.org/0000-0002-5572-196X
Bilge FettahlioGlu Karaman, https://orcid.org/0000-0003-4236-0066
Selma Emre, https://orcid.org/0000-0001-5963-8939
Ersa Adisen, https://orcid.org/0000-0002-8768-231X
Neslihan Sendur, https://orcid.org/0000-0001-7722-5759
Ozlem Bilgic, https://orcid.org/0000-0001-9201-8299
Ayca Cordan Yazici, https://orcid.org/0000-0002-6364-5047
Basak Yalcin, https://orcid.org/0000-0003-2297-1409
Rafet Koca, https://orcid.org/0000-0003-1546-5380
Kamer Gunduz, https://orcid.org/0000-0002-1319-9237
Murat Borlu, https://orcid.org/0000-0003-0824-490X
Tulin Ergun, https://orcid.org/0000-0002-9935-6298
Pinar Dursun, https://orcid.org/0000-0002-6605-5659
Serap Gunes Bilgili, https://orcid.org/0000-0002-4685-885X
Asli Surer Adanir, https://orcid.org/0000-0002-6223-756X
Ayse Serap Karadag, https://orcid.org/0000-0002-1194-095X
Gizem Yagcioglu, https://orcid.org/0000-0003-4936-9258
Ertan Yilmaz, https://orcid.org/0000-0003-0826-7132
Ufuk Kavuzlu, https://orcid.org/0000-0002-5987-7910
Yesim Senol, https://orcid.org/0000-0002-7842-3041

**REFERENCES**

1. Alpsoy E, Polat M, FettahlioGlu-Karaman B, Karadag AS, Kartal-Durmazlar P, YalCin B, et al. Internalized stigma in psoriasis: a multicenter study. J Dermatol 2017;44:885-891.
2. Hawro M, Maurer M, Weller K, Maleszka R, Zalewska-Janowska A, Kaszuba A, et al. Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. J Am Acad Dermatol 2017;76:648-654.
3. Perlick DA, Rosenheck RA, Clarkin JF, Sirey JA, Salahi J, Struening EL, et al. Stigma as a barrier to recovery: adverse effects of perceived stigma on social adaptation of persons diagnosed with bipolar affective disorder. Psychiatr Serv 2001;52:1627-1632.
4. van Beugen S, van Middendorp H, Fenwold E, Smit J, Veenwesen-Fransen ME, Kroft EB, et al. Predictors of perceived stigmatization in patients with psoriasis. Br J Dermatol 2017;
5. Wiencierz S, Williams L. Type D personality and physical inactivity: the mediating effects of low self-efficacy. J Health Psychol 2017;22:1025-1034.

6. Denollet J, Vaes J, Brutsaert DL. Inadequate response to treatment in coronary heart disease: adverse effects of type D personality and younger age on 5-year prognosis and quality of life. Circulation 2000;102:630-635.

7. Ritsher JB, Otilingam PG, Grajales M. Internalized stigma of mental illness: psychometric properties of a new measure. Psychiatry Res 2003;121:31-49.

8. Goffman E. Stigma: notes on the management of spoiled identity. Englewood Cliffs, NJ: Prentice-Hall, 1963.

9. Ross MW, Rosser BR. Measurement and correlates of internalized homophobia: a factor analytic study. J Clin Psychol 1996;52:15-21.

10. Ersoy MA, Varan A. [Reliability and validity of the Turkish version of the internalized stigma of mental illness scale]. Turk Psikiyatri Derg 2007;18:163-171. Turkish.

11. Alpsoy E, Senol Y, Temel AB, Baysal GO, Karakas AA. Psoriasisde içselleştirilmiş stigmatizasyon (damgalanma) ölçeginin güvenirlik ve geçerlik çalışması [Reliability and validity of internalized stigmatization scale in psoriasis]. Türkderm 2015;49:45-49. Turkish.

12. Malmström M, Sundquist J, Johansson SE. Neighborhood environment and self-reported health status: a multilevel analysis. Am J Public Health 1999;89:1181-1186.

13. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979;9:139-145.

14. Ozdemir H, Rezaki M. [General Health Questionnaire-12 for the detection of depression]. Turk Psikiyatri Derg 2007;18:13-21. Turkish.

15. Kilic C, Rezaki M, Rezaki B, Kaplan I, Ozgen G, Sagduyu A, et al. General Health Questionnaire (GHQ12 & GHQ28): psychometric properties and factor structure of the scales in a Turkish primary care sample. Soc Psychiatry Psychiatr Epidemiol 1997;32:327-331.

16. Sirey JA, Bruce ML, Alexopoulos GS, Perlick DA, Friedman SJ, Meyers BS. Stigma as a barrier to recovery: perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence. Psychiatr Serv 2001;52:1615-1620.

17. Wade NG, Post BC, Cornish MA, Vogel DL, Tucker JR. Predictors of the change in self-stigma following a single session of group counseling. J Couns Psychol 2011;58:170-182.

18. Ergun T, Seckin Gencosmanoglu D, Karakoc-Aydiner E, Salman A, Tekin B, Bulbul-Baskan E, et al. Prevalence of obesity in paediatric psoriasis and its impact on disease severity and progression. Australas J Dermatol 2017;58:e182-e187.

19. Pathirana D, Ormerod AD, Siaig P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;Suppl 2:1-70.

20. Alonso J, Buron A, Rojas-Farreras S, de Graaf R, Haro JM, de Girolamo G, et al. Perceived stigma among individuals with common mental disorders. J Affect Disord 2009;118:180-186.